Standard Starting Dose for Juvenile Idiopathic Arthritis
Methotrexate is typically started at 10-15 mg/m² body surface area (BSA) per week for children with juvenile idiopathic arthritis (JIA), given as a single oral dose or divided over 1-2 days. This equates to about 7.5-12.5 mg/m² for younger kids, scaling up based on BSA calculations.[1][2]
How Doses Are Calculated and Adjusted
Doses use BSA (in m²) rather than fixed weight to account for growth. For a child around 20-30 kg (common in JIA patients aged 5-10), this often means 10-20 mg total weekly. Providers increase by 2.5-5 mg/m² every 4-6 weeks if response is inadequate, capping at 25 mg/m²/week (max 30-35 mg total). Blood tests monitor for toxicity before adjustments.[1][3]
Oral vs. Subcutaneous Administration
Oral works for most at lower doses, but subcutaneous injection is common above 15 mg/week for better absorption and fewer GI side effects. Kids tolerate subcutaneous well, often self-injecting after training.[2][4]
What Happens If Doses Are Too High or Too Low?
Overdosing risks liver toxicity, nausea, or bone marrow suppression—monitored via monthly bloodwork (CBC, liver enzymes). Underdosing fails to control joint inflammation. Folic acid (1 mg daily) reduces side effects without weakening efficacy.[1][3]
Age-Specific Considerations and Guidelines
Under 6 years, start lower (7.5-10 mg/m²) due to higher sensitivity. ACR guidelines recommend methotrexate as first-line DMARD for moderate-severe JIA polyarthritis. Doses hold steady through adolescence unless remission occurs.[2][5]
Monitoring and When to Expect Results
Improvement shows in 4-8 weeks; full effect by 3-6 months. If no response, add biologics like etanercept. Long-term use requires annual eye exams for rare retinopathy.[3][4]
Sources
[1] [Arthritis Foundation: Pediatric Methotrexate]
[2] [ACR JIA Guidelines (2019)]
[3] [AAFP: Methotrexate in JIA]
[4] [Cochrane Review: MTX in JIA]
[5] [StatPearls: Juvenile Idiopathic Arthritis]